124 related articles for article (PubMed ID: 36562598)
1. Myofibroblast stroma differentiation in infiltrative basal cell carcinoma is accompanied by regulatory T-cells.
Ressler JM; Zila N; Korosec A; Yu J; Silmbrod R; Bachmayr V; Tittes J; Strobl J; Lichtenberger BM; Hoeller C; Petzelbauer P
J Cutan Pathol; 2023 Jun; 50(6):544-551. PubMed ID: 36562598
[TBL] [Abstract][Full Text] [Related]
2. alpha vbeta 6 Integrin promotes the invasion of morphoeic basal cell carcinoma through stromal modulation.
Marsh D; Dickinson S; Neill GW; Marshall JF; Hart IR; Thomas GJ
Cancer Res; 2008 May; 68(9):3295-303. PubMed ID: 18451156
[TBL] [Abstract][Full Text] [Related]
3. Expression of p16 Protein in Cutaneous Basal Cell Carcinoma: Still far from Being Clearly Understood.
Bartoš V
Acta Dermatovenerol Croat; 2020 Jul; 28(1):43-44. PubMed ID: 32650852
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical Expression of Calponin in Cutaneous Basal Cell Carcinoma.
Bartoš V; Kullová M
Acta Dermatovenerol Croat; 2015; 23(4):254-9. PubMed ID: 26724876
[TBL] [Abstract][Full Text] [Related]
5. Actin expression in purely nodular versus nodular-infiltrative basal cell carcinoma.
Law AM; Oliveri CV; Pacheco-Quinto X; Horenstein MG
J Cutan Pathol; 2003 Apr; 30(4):232-6. PubMed ID: 12680952
[TBL] [Abstract][Full Text] [Related]
6. Human basal cell carcinoma is associated with Foxp3+ T cells in a Th2 dominant microenvironment.
Kaporis HG; Guttman-Yassky E; Lowes MA; Haider AS; Fuentes-Duculan J; Darabi K; Whynot-Ertelt J; Khatcherian A; Cardinale I; Novitskaya I; Krueger JG; Carucci JA
J Invest Dermatol; 2007 Oct; 127(10):2391-8. PubMed ID: 17508019
[TBL] [Abstract][Full Text] [Related]
7. Micronodular basal cell carcinoma: a distinct subtype? Relationship with nodular and infiltrative basal cell carcinomas.
Betti R; Menni S; Radaelli G; Bombonato C; Crosti C
J Dermatol; 2010 Jul; 37(7):611-6. PubMed ID: 20629826
[TBL] [Abstract][Full Text] [Related]
8. Desmoplastic Trichoepithelioma: An Uncommon but Diagnostically Problematic Benign Adnexal Tumor.
Bartoš V
Acta Dermatovenerol Croat; 2019 Dec; 27(4):282-284. PubMed ID: 31969246
[TBL] [Abstract][Full Text] [Related]
9. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma.
Vidal D; Matías-Guiu X; Alomar A
Clin Exp Dermatol; 2004 Sep; 29(5):518-25. PubMed ID: 15347339
[TBL] [Abstract][Full Text] [Related]
10. Increased Marginal Stiffness Differentiates Infiltrative From Noninfiltrative Cutaneous Basal Cell Carcinomas in the Facial Area: A Prospective Study.
Alfageme F; Salgüero I; Nájera L; Suarez ML; Roustan G
J Ultrasound Med; 2019 Jul; 38(7):1841-1845. PubMed ID: 30467885
[TBL] [Abstract][Full Text] [Related]
11. Investigation of P120catenin Expression in Human Basal Cell Carcinoma of the Skin.
Bartoš V; Kullová M
Acta Medica (Hradec Kralove); 2017; 60(1):32-36. PubMed ID: 28591550
[TBL] [Abstract][Full Text] [Related]
12. A retrospective study of 694 Basal Cell Carcinoma excisions to quantify deep margin documentation and clearance compared to histological type and surgical margin.
Kiely JR; Patel AJK
J Plast Reconstr Aesthet Surg; 2019 Nov; 72(11):1805-1812. PubMed ID: 31331722
[TBL] [Abstract][Full Text] [Related]
13. Aesculus hippocastanum L. extract differently modulates normal human dermal fibroblasts and cancer-associated fibroblasts from basal/squamous cell carcinoma.
Melegová N; Čoma M; Urban L; Kaňuchová M; Szabo P; Smetana K; Mučaji P; Gál P
Neoplasma; 2022 Jan; 69(1):224-232. PubMed ID: 34962824
[TBL] [Abstract][Full Text] [Related]
14. Dysregulated expression of transforming growth factor beta and its type-I and type-II receptors in basal-cell carcinoma.
Furue M; Kato M; Nakamura K; Nashiro K; Kikuchi K; Okochi H; Miyazono K; Tamaki K
Int J Cancer; 1997 May; 71(4):505-9. PubMed ID: 9178800
[TBL] [Abstract][Full Text] [Related]
15. Immunosuppressive Environment in Basal Cell Carcinoma: The Role of Regulatory T Cells.
Omland SH; Nielsen PS; Gjerdrum LM; Gniadecki R
Acta Derm Venereol; 2016 Nov; 96(7):917-921. PubMed ID: 27117439
[TBL] [Abstract][Full Text] [Related]
16. Local immune response in cutaneous basal cell carcinoma.
Omland SH
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975891
[TBL] [Abstract][Full Text] [Related]
17. Basal cell carcinoma progression correlates with host immune response and stromal alterations: a histologic analysis.
Kaur P; Mulvaney M; Carlson JA
Am J Dermatopathol; 2006 Aug; 28(4):293-307. PubMed ID: 16871032
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of programmed cell death ligand 1 (PD-L1) and inflammatory cells in basal cell carcinoma subtypes.
Gompertz-Mattar M; Perales J; Sahu A; Mondaca S; Gonzalez S; Uribe P; Navarrete-Dechent C
Arch Dermatol Res; 2022 Oct; 314(8):777-786. PubMed ID: 34647186
[TBL] [Abstract][Full Text] [Related]
19. Induction of chemokine receptor CXCR4 expression by transforming growth factor-β1 in human basal cell carcinoma cells.
Chu CY; Sheen YS; Cha ST; Hu YF; Tan CT; Chiu HC; Chang CC; Chen MW; Kuo ML; Jee SH
J Dermatol Sci; 2013 Nov; 72(2):123-33. PubMed ID: 23856244
[TBL] [Abstract][Full Text] [Related]
20. GREM1 is expressed in the cancer-associated myofibroblasts of basal cell carcinomas.
Kim HS; Shin MS; Cheon MS; Kim JW; Lee C; Kim WH; Kim YS; Jang BG
PLoS One; 2017; 12(3):e0174565. PubMed ID: 28346486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
